Evaluation of quantitative modeling methods in whole-body, dynamic [¹¹C]-erlotinib PET.

ABSTRACT:

Background

[¹¹C]-Erlotinib is a radiolabeled analogue of a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) which expresses specific kinase domain mutations of the epidermal growth factor receptor (EGFR). In this study, 10 subjects with NSCLC and assorted EGFR mutation status underwent a dynamic, multi-bed positron emission tomography (PET) scan using [¹¹C]-erlotinib. Data were analyzed using a variety of quantitative techniques common in PET (graphical methods, kinetic models, and uptake value-based endpoints). Our primary goal was to determine the most reliable imaging endpoint given the need for maintaining minimal patient burden and recognizing the advantage of simple calculations in future trials.

Results

Standard uptake v

SUBMITTER: Petrulli JR 

PROVIDER: S-EPMC8165727 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature